Elite Pharmaceuticals, Inc. (ELTP)
Market Cap | 125.39M |
Revenue (ttm) | 47.32M |
Net Income (ttm) | 15.55M |
Shares Out | 1.02B |
EPS (ttm) | 0.02 |
PE Ratio | 8.16 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 797,573 |
Open | 0.128 |
Previous Close | 0.127 |
Day's Range | 0.121 - 0.128 |
52-Week Range | 0.030 - 0.210 |
Beta | -0.14 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 14, 2023 |
About ELTP
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P ... [Read more]
Full Company ProfileFinancial Performance
In 2022, ELTP's revenue was $34.16 billion, an increase of 105767.55% compared to the previous year's $32.26 million. Earnings were $4.41 billion, an increase of 49459.23%.
Financial StatementsNews
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pha...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Financials for Third Quarter Fiscal Year 2024 Ended December 31, 2023 will be released on February 14, 2024 NORTHVALE, NJ / ACCESSWIRE / February 8, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the ...
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
NORTHVALE, NJ / ACCESSWIRE / December 26, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and di...
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
NORTHVALE, NJ / ACCESSWIRE / December 12, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announ...
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
Conference Call Scheduled for Wednesday, November 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / November 14, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty p...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
Financials for Second Quarter Fiscal Year 2024 Ended September 30, 2023 will be released on November 14, 2023 NORTHVALE, NJ / ACCESSWIRE / November 10, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or t...
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
NORTHVALE, NJ / ACCESSWIRE / September 25, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and di...
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
NORTHVALE, NJ / ACCESSWIRE / September 7, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic prod...
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
NORTHVALE, NJ / ACCESSWIRE / August 28, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distr...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
Financials for First Quarter Fiscal Year 2024 Ended June 30, 2023 will be released on August 14, 2023 NORTHVALE, NJ / ACCESSWIRE / August 9, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information
Conference Call Scheduled for Friday, June 30 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 29, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutic...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023
Financials for Fiscal Year 2023 Ended March 31, 2023 will be released on June 29, 2023 NORTHVALE, NJ / ACCESSWIRE / June 22, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP),...
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
NORTHVALE, NJ / ACCESSWIRE / May 3, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, ...
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product
NORTHVALE, NJ / ACCESSWIRE / April 20, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information
Conference Call Scheduled for Wednesday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty p...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2023 Financial Results on February 15, 2023
Financials for Third Quarter Fiscal Year 2023 Ended December 31, 2022 will be released on February 14, 2023 NORTHVALE, NJ / ACCESSWIRE / February 8, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the ...
Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist
NORTHVALE, NJ / ACCESSWIRE / December 22, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announ...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 Ended September 30, 2022 and Provides Conference Call Information
Conference Call Scheduled for Tuesday, November 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / November 15, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty phar...
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2023 ended June 30, 2022, and Provides Conference Call Information
Conference Call Scheduled for Tuesday, August 16 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / August 15, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmace...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2023 Financial Results on August 16, 2022
Financials for First Quarter Fiscal Year 2023 Ended June 30, 2022 will be released on August 15, 2022 NORTHVALE, NJ / ACCESSWIRE / August 11, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Compan...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information
Conference Call Scheduled for Thursday, June 30 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceut...
Elite Pharmaceuticals Receives FDA Approval for Generic Sabril(R)
NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced ...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2022 Financial Results on June 30, 2022
Financials for Fiscal Year 2022 Ended March 31, 2022 will be released on June 29, 2022 NORTHVALE, NJ / ACCESSWIRE / June 23, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP),...
Elite Pharmaceuticals, Inc. Appoints Robert Chen as Chief Financial Officer
NORTHVALE, NJ / ACCESSWIRE / May 11, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products,...
Elite Pharmaceuticals and Praxgen Pharmaceuticals Receive FDA Approval for Generic Doxycycline
NORTHVALE, NJ / ACCESSWIRE / April 4, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced ...